TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02763566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly
Study: NCT03483610

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider Referral
Description: Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
Study: NCT04088409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT00002540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03039790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.
Study: NCT00922272

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching SPD489 (lisdexamfetamine dimesylate)
Description: oral, once daily
Study: NCT03039790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.
Study: NCT02959190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT05164887

Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal resection
Description: the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
Study: NCT04502823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management based on sFlt-1/PlGF values
Description: In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks.
Study: NCT04419792

Intervention type: OTHER
Intervention: Assessment of physical performance variables
Description: Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test
Study: NCT04549753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current simulation
Description: Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
Study: NCT02959190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT03480386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Pulmonary Rehabilitation
Description: Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
Study: NCT04186923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-SPOKE
Description: This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
Study: NCT02959190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT00776334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril 40mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril 40mg Tablets
Study: NCT02979028

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Transcutaneous electrical acupoint stimulation
Study: NCT04328441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracutaneously 0.1ml NaCl 0,9%
Study: NCT01007513

Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound
Description: A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.

Intervention type: PROCEDURE
Intervention: Vaginal secretion sampling
Description: Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
Study: NCT04430790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxapram
Description: Loading dose and continuous doxapram infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose and continuous placebo infusion.
Study: NCT00049504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo haploidentical hematopoietic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo haploidentical hematopoietic bone marrow transplantation
Study: NCT02575300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT03431792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Tail Balloon
Description: s. description of experimental Arm
Study: NCT01522768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib and Paclitaxel
Description: All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
Study: NCT04523467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-angiogenic Targeted Drugs
Description: A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rg3
Description: An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
Study: NCT04732572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and healthy lifestyle education
Description: Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and healthy lifestyle education
Description: Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other supportive care
Description: Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other supportive care
Description: Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
Study: NCT00615459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 μg or 300 μg, delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 μg or 300 μg, delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 μg or 300 μg, delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 μg or 300 μg, delivered via SDDPI
Study: NCT01846013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand
Description: Stand at least half of the workday at work.
Study: NCT00615459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 μg once daily delivered via inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 μg once daily delivered via inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 μg once daily delivered via inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
Study: NCT00736593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon™ or Nexagon™ vehicle
Study: NCT03148795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg daily
Study: NCT04399252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Participants will take 2 capsules per day of either LGG or placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus rhamnosus GG Placebo
Description: Participants will take 2 capsules per day of LGG placebo
Study: NCT04306757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Airway ventilation device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primus
Description: Airway ventilation device
Study: NCT00663104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: exercise: 3 joint sessions/week for 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise + cimicifuga racemosa
Description: exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: wellness control, placebo
Description: 2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
Study: NCT03986567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gamification for partner notification among youngsters
Description: Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gamification for partner notification among youngsters
Description: Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gamification for partner notification among youngsters
Description: Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification
Study: NCT00468611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP8298
Description: 500mg MBP8298 IV every six months for a period of two years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MBP8298
Description: 500mg MBP8298 IV every six months for a period of two years
Study: NCT02746445

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
Study: NCT01917552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1250 milligram (mg) / m² po bid (D1-14)
Study: NCT02017704

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Endo-HDR (if randomized to this arm)
Description: Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine and IMRT (if randomized to this arm)
Description: Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT (intensity modulated radiation therapy)
Description: Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
Study: NCT01846013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move
Description: Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand and Move
Description: Increase standing time to half of workday (4h) and increase movement time at work.
Study: NCT00699374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
Study: NCT02065700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered as Oral Tablets
Study: NCT00859586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi Magnetic cell sorter for CD3
Description: Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
Study: NCT00678197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bonus/Pay-for-Performance Intervention
Study: NCT02747550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LM with TESTO
Description: In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LM without TESTO
Description: In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
Study: NCT01480843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults